Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Khiron Life Sciences Corp KHRWF


Primary Symbol: V.KHRN.H Alternate Symbol(s):  V.KHRN.WT.H | KHRNF

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by nocashnoluckon Mar 05, 2021 12:53pm
155 Views
Post# 32729169

RE:RE:Khiron newsletter Mar 4 2021

RE:RE:Khiron newsletter Mar 4 2021
zardoz00 wrote: Excerpt from the newsletter:

  • Khiron has issued over 10,000 medical cannabis paid prescriptions and reports a significant increase in written prescriptions since the inclusion of the company’s products and services under health insurance policies in Colombia.
  • On a per-capita basis, the company’s patient volumes in Bogota put Khiron in line with countries like Canada and Germany and its initial growth rates exceed industry leaders like Trulieve back in 2017.
  • In the global context, Khiron’s retail prices remain very strong, currently in the CAD 50-60/unit range, which is above or on par with average tincture prices in markets like Canada.
  • The company has achieved a 50% compound monthly growth in paid prescriptions since April last year.
  • By being vertically integrated, with four wholly-owned clinics and high-quality cultivation and extraction assets, Khiron is generating industry-leading margins, currently over 80%. 
  • 92% of the company’s patients report an improvement in their primary condition after four months of treatment.
  • During the last 2 months, Khiron had made almost 50% of the total written medical cannabis prescriptions done in 2020.


this is grat! I`m loading up with KHRN warrant!!!
<< Previous
Bullboard Posts
Next >>